Drugs / SB773812
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00500201 | May → Jul 2007 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00411866 | Oct 2006 → Oct 2007 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00269035 | Jun 2005 → May 2007 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00197093 | Sep 2004 → ? | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00259870 | Sep 2005 → Aug 2007 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB773812 | “A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and...” NCT00197093 ↗7“A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.” NCT00500201 ↗ “single oral dose of SB-773812 20 milligrams (mg)” NCT00411866 ↗ |
| Known as | GW773812 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314394 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL5314394 ↗1“Dopamine D2 receptor antagonist” CHEMBL5314394 ↗ |
| Modality | Small molecule | — CHEMBL5314394 ↗ |
| Route | Oral | “Ascending Multiple Oral Doses” NCT00197093 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL5314394 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL5314394 ↗ |